An analysis conducted on a 2021 poll has released results indicating that most patients suffering from plaque psoriasis have reported symptoms in intertriginous areas, which sometimes prevents them from seeking medical guidance. The researchers looked into the sexual, psychosocial and mental impact of such symptoms on the affected patients and found that roughly two-thirds of patients would like to have therapy options to treat psoriasis in these areas.
A team of U.S. researchers, led by Teri Greiling, conducted the analysis of the Harris Poll’s findings and presented their results at this year’s Society of Dermatology Physician Assistants annual meeting. Greiling is the associate program director of research and dermatology at the School of Medicine in Oregon Health & Science University.
The researchers’ findings show that most adult patients with psoriasis agreed that symptoms that affected intertriginous areas such as beneath breast and stomach folds, the groin, between the buttocks and in armpits negatively impacted their quality of life in many ways.
The researchers found that redness, scaling and itching were common symptoms that drove negative impact on patient quality of life. They also found that roughly 67% of the patients suffered from moderate psoriasis, noting that of this number, about 70% preferred topical therapies.
Of the total number of respondents, almost 65% revealed that they suffered psoriasis symptoms in intertriginous areas, with researchers highlighting that the most commonly affected areas were in the armpits and between the buttocks. Patients who had symptoms in these areas reported that they were embarrassed about it 80% of the time, while 69% of them reported experiencing depression as a result. Another 79% of the patients also reported experiencing anxiety.
In addition, patients with psoriasis symptoms in these areas also reported that the disease had a strong and/or negative impact on their sexual function and intimate relationships as well as their anxiety and sexual distress. The researchers observe that each of these components was more common in patients who had psoriasis in their nether region.
Furthermore, the researchers observed that few patients who experienced these symptoms in intertriginous areas told their healthcare providers. Instead, they preferred to self-treat symptoms without discussing the situation with a clinician.
In their report, the researchers stated that of the 507 patients who responded, 44% were women, adding that the mean age of patients who participated in the poll was 45.1 years.
The researchers highlight the need to improve treatment options for different states of this illness and improving communication between patients and their physicians.
Companies such as BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) are focused on finding better treatments for ailments such as psoriasis so that patients will no longer have to be embarrassed each time a flare up occurs and a doctor has to examine them or administer medicine in intertriginous parts of the body.
NOTE TO INVESTORS: The latest news and updates relating to BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) are available in the company’s newsroom at https://ibn.fm/BVXV
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
